Sequenom (SQNM) looks to retrace yesterday's losses after Wedbush says a WSJ article about proposed regulation of prenatal screening tests likely overstates the case as the FDA "has missed its window to regulate the non-invasive prenatal testing market." Analyst Zarak Khurshid upgrades the stock to Outperform from Neutral and reiterates a price target of $5. Shares +3.4% premarket.
Sequenom (SQNM) looks to retrace yesterday's losses after Wedbush says a WSJ article about...
From other sites
at CNBC.com (Dec 3, 2014)
at CNBC.com (Jan 14, 2014)
at CNBC.com (Mar 15, 2013)
at CNBC.com (Apr 25, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs